FDA approves oral treatment for opioid-induced constipation

The FDA has approved the oral treatment for opioid-induced constipation naloxegol (Movantik), according to a Gastroenterology & Endoscopy News report.

Movantik is designed for adults with chronic non-cancer pain. The drug is a peripherally acting mu-opiod-receptor antagonist used to decrease the constipation side effect of opioids, according to the report.

More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
AGA releases new tool for Crohn's disease treatment
How has the Obama presidency affected the field of GI?

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast